| Niraparib studied in …STUDIED_INderived173 of 173show fewer |
|---|
| → studied in | NCT03431350Phase 2 · active not recruiting A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer · 173 trials list this drug (67 active) | — | — | Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03748641Phase 3 · active not recruiting A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer · 173 trials list this drug (67 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04577833Phase 1 · active not recruiting A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer · 173 trials list this drug (67 active) | — | — | Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04584255Phase 2 · active not recruiting Niraparib + Dostarlimab In BRCA Mutated Breast Cancer · 173 trials list this drug (67 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03891615Phase 1 · terminated Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer · 173 trials list this drug (67 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06915025Phase 3 · recruiting Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer · 173 trials list this drug (67 active) | — | — | Primary Peritoneal Carcinoma,Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06433219Phase 2 · completed Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) · 173 trials list this drug (67 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03651206Phase 2/Phase 3 · recruiting Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib · 173 trials list this drug (67 active) | — | — | Uterine Corpus Carcinosarcoma,Ovarian Carcinosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04592237Phase 2 · active not recruiting Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer · 173 trials list this drug (67 active) | — | — | Prostate Neuroendocrine Carcinoma,Malignant Prostate Neoplasm,Prostate Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04493060Phase 2 · completed Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer · 173 trials list this drug (67 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05515575Phase 2 · active not recruiting A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA · 173 trials list this drug (67 active) | — | — | Sarcoma,Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06682780Phase 1/Phase 2 · recruiting A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours · 173 trials list this drug (67 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07783022recruiting Real-World Study of Niraparib in First-Line Maintenance Therapy for Advanced Epithelial Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04673448Phase 1 · active not recruiting Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer · 173 trials list this drug (67 active) | — | — | Malignant Solid Neoplasm,Breast Carcinoma,Malignant Pancreatic Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04812366Phase 2 · recruiting Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer · 173 trials list this drug (67 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04170153Phase 1 · active not recruiting Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) · 173 trials list this drug (67 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06412120Phase 4 · recruiting Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · 173 trials list this drug (67 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03869190Phase 1/Phase 2 · terminated Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) · 173 trials list this drug (67 active) | — | — | Urothelial Carcinoma,Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03768063Phase 3 · active not recruiting A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study · 173 trials list this drug (67 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05406700early Phase 1 · active not recruiting Niraparib In Recurrent IDH 1/2 Gliomas · 173 trials list this drug (67 active) | — | — | Glioma,Low Grade Glioma,Malignant Glioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03586661Phase 1 · completed Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · 173 trials list this drug (67 active) | — | — | Primary Peritoneal Carcinoma,Ovarian Carcinoma,Endometrial Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04992013Phase 2 · active not recruiting Niraparib in Tumors Metastatic to the CNS · 173 trials list this drug (67 active) | — | — | Malignant Neoplasm,Malignant Central Nervous System Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05990192Phase 2 · recruiting SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy · 173 trials list this drug (67 active) | — | — | Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04037254Phase 1/Phase 2 · completed Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring · 173 trials list this drug (67 active) | — | — | Prostate Adenocarcinoma,Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06388733Phase 3 · active not recruiting A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma · 173 trials list this drug (67 active) | — | — | Glioblastoma,Brain Neoplasm,Adult Malignant Brain Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04926324Phase 1 · terminated A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers · 173 trials list this drug (67 active) | — | — | Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04641247Phase 2 · recruiting A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study · 173 trials list this drug (67 active) | — | — | Breast Neoplasm,Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03016338Phase 2 · active not recruiting Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer · 173 trials list this drug (67 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04947254Phase 2 · recruiting Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer · 173 trials list this drug (67 active) | — | — | Malignant Prostate Neoplasm,Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04475939Phase 3 · completed Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer · 173 trials list this drug (67 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05694715Phase 1 · recruiting Combination Therapy in Cancers With Mutations in DNA Repair Genes · 173 trials list this drug (67 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03945721Phase 1 · active not recruiting A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients · 173 trials list this drug (67 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04837209Phase 2 · active not recruiting Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer · 173 trials list this drug (67 active) | — | — | Malignant Breast Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05784012Phase 1/Phase 2 · active not recruiting Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma · 173 trials list this drug (67 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05523440Phase 2 · terminated Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation · 173 trials list this drug (67 active) | — | — | Ovarian Carcinoma,Endometrial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05718323Phase 2 · recruiting Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC · 173 trials list this drug (67 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05615818Phase 3 · recruiting Personalized Medicine for Advanced Biliary Cancer Patients · 173 trials list this drug (67 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04030559Phase 2 · terminated Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects · 173 trials list this drug (67 active) | — | — | Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04502602Phase 1 · active not recruiting Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Solid Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04313504Phase 2 · completed Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC · 173 trials list this drug (67 active) | — | — | Malignant Head and Neck Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05601440Phase 2 · recruiting Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer · 173 trials list this drug (67 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04194554Phase 1/Phase 2 · active not recruiting A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer · 173 trials list this drug (67 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06077877Phase 1/Phase 2 · active not recruiting A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors · 173 trials list this drug (67 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04701307Phase 2 · active not recruiting Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas · 173 trials list this drug (67 active) | — | — | Malignant Lung Neoplasm,Neuroendocrine Carcinoma,Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06180356Phase 2 · recruiting Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression · 173 trials list this drug (67 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05021562completed A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice · 173 trials list this drug (67 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05183984Phase 2 · recruiting Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer · 173 trials list this drug (67 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05335993Phase 2 · active not recruiting A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. · 173 trials list this drug (67 active) | — | — | Malignant Peritoneal Neoplasm,Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05870761Phase 2 · active not recruiting Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma · 173 trials list this drug (67 active) | — | — | Endometrial Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03601923Phase 2 · completed Niraparib in Patients With Pancreatic Cancer · 173 trials list this drug (67 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05198804Phase 1/Phase 2 · completed A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Primary Peritoneal Carcinoma,Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02655016Phase 3 · active not recruiting A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy · 173 trials list this drug (67 active) | — | — | Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05076513early Phase 1 · active not recruiting Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma · 173 trials list this drug (67 active) | — | — | Glioblastoma,Glioma,Brain Glioblastoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05442749Phase 2 · terminated Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer · 173 trials list this drug (67 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03830918Phase 1/Phase 2 · active not recruiting Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy · 173 trials list this drug (67 active) | — | — | Malignant Solid Neoplasm,Malignant Lung Neoplasm,Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04068753Phase 2 · active not recruiting Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer · 173 trials list this drug (67 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05700721Phase 2 · recruiting Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET) · 173 trials list this drug (67 active) | — | — | Brain Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06086665completed The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04481113Phase 1 · completed Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer · 173 trials list this drug (67 active) | — | — | Breast Carcinoma,Invasive Breast Carcinoma,HER2-Negative Breast Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04991480Phase 1 · completed A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors · 173 trials list this drug (67 active) | — | — | Malignant Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03368729Phase 1/Phase 2 · active not recruiting Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer · 173 trials list this drug (67 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04544995Phase 1 · terminated Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP) · 173 trials list this drug (67 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04221503Phase 2 · active not recruiting Niraparib/TTFields in GBM · 173 trials list this drug (67 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03983993Phase 2 · active not recruiting Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer · 173 trials list this drug (67 active) | — | — | Malignant Colorectal Neoplasm,Microsatellite Stable Colorectal Carcinoma,MSI-H Colorectal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03602859Phase 3 · active not recruiting A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02854436Phase 2 · completed An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies · 173 trials list this drug (67 active) | — | — | Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05526989Phase 2 · recruiting Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma · 173 trials list this drug (67 active) | — | — | Penile Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04779151Phase 2 · terminated Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab · 173 trials list this drug (67 active) | — | — | Malignant Head and Neck Neoplasm,Malignant Biliary Tract Neoplasm,Urothelial Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06964165Phase 2 · terminated A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C) · 173 trials list this drug (67 active) | — | — | Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03307785Phase 1 · completed Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 · 173 trials list this drug (67 active) | — | — | Neoplasm,Malignant Neoplasm,Solid Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05169437Phase 2 · terminated Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors · 173 trials list this drug (67 active) | — | — | Breast Neoplasm,Malignant Neoplasm,Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06747845Phase 2 · recruiting Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy · 173 trials list this drug (67 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05009082Phase 3 · recruiting Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Malignant Peritoneal Neoplasm,Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03981796Phase 3 · active not recruiting A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer · 173 trials list this drug (67 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04080284Phase 2 · completed Trial of Maintenance With Niraparib- Uterine Serous Carcinoma · 173 trials list this drug (67 active) | — | — | Endometrial Carcinoma,Endometrial Serous Adenocarcinoma,Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04409002Phase 2 · completed Niraparib + Dostarlimab + RT in Pancreatic Cancer · 173 trials list this drug (67 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04159155Phase 2/Phase 3 · terminated A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer · 173 trials list this drug (67 active) | — | — | Endometrial Carcinoma,Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03326193Phase 2 · completed A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy · 173 trials list this drug (67 active) | — | — | Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04341181Phase 2 · recruiting ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling · 173 trials list this drug (67 active) | — | — | Neoplasm,Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04915755Phase 3 · active not recruiting Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease · 173 trials list this drug (67 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03574779Phase 2 · completed A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07059676not yet recruiting Design and Validation of Plasma Proteins and Cytokine Panels to Identify Markers Associated With Response to Niraparib as Maintenance Treatment After First-line Platinum-based Regimen in Patients With Advanced Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03783949Phase 2 · completed European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Primary Peritoneal Carcinoma,Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05297864Phase 2 · terminated PARP Inhibition for Gliomas (PI-4G or π4g) · 173 trials list this drug (67 active) | — | — | Glioblastoma,Glioma,Astrocytoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05672095Phase 1/Phase 2 · withdrawn Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Primary Peritoneal Carcinoma,Ovarian Carcinoma,Platinum-Resistant Primary Peritoneal Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03076203Phase 1 · completed Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad) · 173 trials list this drug (67 active) | — | — | Prostate Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05126342Phase 2 · withdrawn Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi · 173 trials list this drug (67 active) | — | — | Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06594679Phase 1/Phase 2 · recruiting A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL) · 173 trials list this drug (67 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06887933Phase 4 · not yet recruiting A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04423185Phase 2 · recruiting PLATFORM Study of Precision Medicine for Rare Tumors · 173 trials list this drug (67 active) | — | — | Rare Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06365970Phase 2 · withdrawn Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers · 173 trials list this drug (67 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03891576Phase 2 · terminated Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer) · 173 trials list this drug (67 active) | — | — | Primary Peritoneal Carcinoma,Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03329937Phase 1 · completed Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer · 173 trials list this drug (67 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05289648early Phase 1 · withdrawn Niraparib in High-grade Endometrial Cancer Trial · 173 trials list this drug (67 active) | — | — | Serous Adenocarcinoma,Uterine Neoplasm,Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04507841Phase 2 · active not recruiting Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03752216Phase 4 · completed NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib. · 173 trials list this drug (67 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04826198Phase 1/Phase 2 · terminated Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months · 173 trials list this drug (67 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06614790recruiting Niraparib Maintenance Treatment in Patients With Newly Diagnosed Advanced Platinum- Sensitive, OC. The First Poland RWE Study. · 173 trials list this drug (67 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06161493Phase 1 · withdrawn ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors · 173 trials list this drug (67 active) | — | — | Solid Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03598270Phase 3 · completed Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06258018Phase 1/Phase 2 · not yet recruiting Niraparib and Temozolomide in Patients Glioblastoma · 173 trials list this drug (67 active) | — | — | Malignant Glioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04185831Phase 2 · unknown A MolEcularly Guided Anti-Cancer Drug Off-Label Trial · 173 trials list this drug (67 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03154281Phase 1 · completed Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast · 173 trials list this drug (67 active) | — | — | Malignant Breast Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03329001Phase 1 · completed Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule · 173 trials list this drug (67 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03759600Phase 2 · completed Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03759587Phase 2 · completed Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03840967Phase 2 · terminated A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma · 173 trials list this drug (67 active) | — | — | Adenocarcinoma,Malignant Esophageal Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05666349Phase 1 · withdrawn Reirradiation and Niraparib in Patients With Recurrent Glioblastoma · 173 trials list this drug (67 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04240106Phase 2 · completed Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN) · 173 trials list this drug (67 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03209401Phase 1 · terminated Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies · 173 trials list this drug (67 active) | — | — | Adult Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06237205Phase 2 · not yet recruiting Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency · 173 trials list this drug (67 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02925234Phase 2 · recruiting The Drug Rediscovery Protocol (DRUP Trial) · 173 trials list this drug (67 active) | — | — | Neoplasm,Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05238831early Phase 1 · withdrawn SMMART Adaptive Clinical Treatment (ACT) Trial · 173 trials list this drug (67 active) | — | — | Malignant Solid Neoplasm,Sarcoma,Breast Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05065021Phase 2 · unknown Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor · 173 trials list this drug (67 active) | — | — | Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04716686Phase 2 · recruiting Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma · 173 trials list this drug (67 active) | — | — | Endometrial Carcinoma,Ovarian Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04267939Phase 1 · terminated ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Solid Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04284852Phase 2 · completed Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant Setting · 173 trials list this drug (67 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05261269Phase 1 · completed A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer · 173 trials list this drug (67 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05961124Phase 2 · recruiting Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Malignant Ovarian Neoplasm,Ovarian High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06141265Phase 2 · recruiting Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab · 173 trials list this drug (67 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03088059Phase 2 · unknown Biomarker-based Study in R/M SCCHN · 173 trials list this drug (67 active) | — | — | Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03308942Phase 2 · completed Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants · 173 trials list this drug (67 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05174455Phase 2 · withdrawn Niraparib for the Treatment of Leiomyosarcoma · 173 trials list this drug (67 active) | — | — | Leiomyosarcoma,Retroperitoneal Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03207347Phase 2 · completed A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) · 173 trials list this drug (67 active) | — | — | Malignant Mesothelioma,Uveal Melanoma,Cholangiocarcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05412706Phase 2 · withdrawn Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy · 173 trials list this drug (67 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03695380Phase 1 · completed A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01847274Phase 3 · completed A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Ovarian Neoplasm,Platinum-Sensitive Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05751629Phase 2 · completed Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05734911completed Effectiveness and Safety of Niraparib as First-line Maintenance Therapy for Ovarian Cancer: a Real-world Study · 173 trials list this drug (67 active) | — | — | Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05130515Phase 2 · completed Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma. · 173 trials list this drug (67 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05641506Phase 2 · unknown A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02657889Phase 1/Phase 2 · completed Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Neoplasm,Malignant Breast Neoplasm,Malignant Peritoneal Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01905592Phase 3 · terminated A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients · 173 trials list this drug (67 active) | — | — | Breast Neoplasm,Breast Carcinoma,Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02354586Phase 2 · completed A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens · 173 trials list this drug (67 active) | — | — | Ovarian Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03955471Phase 2 · terminated Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02354131Phase 1/Phase 2 · completed Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04681469Phase 2 · recruiting Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC · 173 trials list this drug (67 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02826512Phase 2 · terminated A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients · 173 trials list this drug (67 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05461690Phase 2 · unknown Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency · 173 trials list this drug (67 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04895046Phase 2 · withdrawn Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma · 173 trials list this drug (67 active) | — | — | Malignant Neoplasm,Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03945084Phase 2 · completed Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy · 173 trials list this drug (67 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05385068Phase 2 · unknown A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi · 173 trials list this drug (67 active) | — | — | Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05162196Phase 2 · unknown The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer · 173 trials list this drug (67 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04762901Phase 1 · withdrawn LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer · 173 trials list this drug (67 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03983226Phase 2 · recruiting Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) · 173 trials list this drug (67 active) | — | — | Fallopian Tube Neoplasm,Primary Peritoneal Carcinoma,Malignant Fallopian Tube Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05232006Phase 2 · not yet recruiting PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers · 173 trials list this drug (67 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03221400Phase 1/Phase 2 · unknown PEN-866 in Patients With Advanced Solid Malignancies · 173 trials list this drug (67 active) | — | — | Neoplasm,Malignant Neoplasm,Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05187208Phase 4 · unknown PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Malignant Ovarian Neoplasm,Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03497429Phase 1 · completed A Study of Niraparib as Single Agent in Participants With Advanced Solid Tumors · 173 trials list this drug (67 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03925350Phase 2 · unknown Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation · 173 trials list this drug (67 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04217798Phase 2 · unknown Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04679064Phase 3 · unknown Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment · 173 trials list this drug (67 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04546373completed Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Malignant Fallopian Tube Neoplasm,Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04986371unknown Real-world Study of Niraparib Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03806049Phase 3 · withdrawn Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04655183Phase 1/Phase 2 · withdrawn Study of M4344 in Combination With Niraparib · 173 trials list this drug (67 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03359850Phase 1 · completed Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients · 173 trials list this drug (67 active) | — | — | Neoplasm,Solid Neoplasm,Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04785716completed Real-life Use of Niraparib in a Patient Access Program in Norway · 173 trials list this drug (67 active) | — | — | Malignant Peritoneal Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04764084Phase 1 · unknown Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors · 173 trials list this drug (67 active) | — | — | Malignant Pancreatic Neoplasm,Cholangiocarcinoma,Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04715620Phase 2 · unknown Niraparib Combined With Radiotherapy in rGBM · 173 trials list this drug (67 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02044120Phase 1 · completed ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma · 173 trials list this drug (67 active) | — | — | Ewing Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04376073Phase 2 · unknown Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04556071Phase 2 · unknown Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Neoplasm,Neoplasm by Site,Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02924766Phase 1 · completed A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE) · 173 trials list this drug (67 active) | — | — | Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02476552Phase 1 · completed Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailability of Niraparib in Subjects With Cancer · 173 trials list this drug (67 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02500901Phase 1 · terminated Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC) · 173 trials list this drug (67 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03895788Phase 1 · unknown A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03025867approved for marketing Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer · 173 trials list this drug (67 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01244009Phase 2 · withdrawn A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002) · 173 trials list this drug (67 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01110603Phase 1 · terminated A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1) · 173 trials list this drug (67 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00749502Phase 1 · completed A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8) · 173 trials list this drug (67 active) | — | — | Solid Neoplasm,Chronic Lymphocytic Leukemia,T-Cell Prolymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01294735Phase 1 · completed Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1) · 173 trials list this drug (67 active) | — | — | Melanoma,Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01226901Phase 1 · terminated A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005) · 173 trials list this drug (67 active) | — | — | Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |